Replies to post #118985 on Biotech Values

[zipjet]

OK so mL is now running at 44.8% of the US market of ~$2.3B, or ~$1.0B. So there is some room for greater mL sales in the US.

But the bigger target would be ROW sales or another $2.1B. Is NVS seeking EU approval or any other xUS approval?

ij

[dewophile]

it's nice to see the numbers finally make sense now that inventory levels seem to be more or less in steady state (if you recall i was perplexed after last quarter's nvs cc when jeff george responded that the 170M was in line with 40% market share)
the 560M in lovenox sales for the quarter - assuming no growth from peak sales before mL was approved - translates to about a 20% pricing discount for the product as a whole
all in all i think NVS has done an excellent job in selling lovenox. the pricing translates to over 500M in annual savings to the US healthcare market, which from a commercial and public relations standpoint seems just right. they began targeting retail which is slightly higher margin than hospital. and in less than a year are close to that perfect 50-50 split of the market which one would expect in a duopoly